Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. After securing a unique accelerated approval not quite six months ago, the ...

DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial Using AI, we identified publications ...